A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA.

被引：0
|
作者：
Nauseef, Jones T.
Sun, Michael Philip
Thomas, Charlene
Bissassar, Mahelia
Patel, Amie
Tan, Angela
Fernandez, Escarleth
Davidson, Zachary
Chamberlain, Tessa
Earle, Kara
Wunder, Rebecca
Castellanos, Sandra Huicochea
Gregos, Peter
Osborne, Joseph
Ballman, Karla V.
Molina, Ana M.
Sternberg, Cora N.
Nanus, David M.
Bander, Neil Harrison
Tagawa, Scott T.
机构：
[1] Weill Cornell Med, Div Hematol & Med Oncol, New York, NY USA
[2] Sandra & Edward Meyer Canc Ctr, New York, NY USA
[3] Weill Cornell Med, Div Hematol & Med Oncol, New York, NY USA
[4] Weill Cornell Med, New York, NY USA
[5] Weill Cornell Med Ctr, New York, NY USA
[6] Weill Cornell Med Coll, New York, NY USA
[7] Weill Cornell Med Mol Imaging & Therapeut, Dept Radiol, New York, NY USA
[8] NYP Brooklyn Methodist Hosp, Weill Cornell Med, Brooklyn, NY USA
[9] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA
[10] Cornell Univ, Weill Med Coll, NewYork Presbyterian Hosp, New York, NY USA
[11] Weill Cornell Med, Hematol Oncol, New York, NY USA
[12] NewYork Presbyterian Hosp, Div Hematol & Med Oncol, Weill Cornell Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS288
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Fractionated dose radiolabeled antiprostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) with or without docetaxel for metastatic castration-resistant prostate cancer (mCRPC)
    Batra, Jaspreet S.
    Karir, Beerinder S.
    Vallabheiesula, Shenker
    Christos, Paul J.
    Hodes, Gillian
    Date, Pravin R.
    Nikolopoulou, Anastasia
    Jhanwar, Yuliya
    Beltran, Himisha
    Nanus, David M.
    Goldsmith, Stanley J.
    Bander, Nell Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [22] Pilot study of "hyperfractionated" anti-prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) for progressive metastatic castration-resistant prostate cancer (mCRPC)
    Molina, Ana M.
    Batra, Jaspreet S.
    Karir, Beerinder S.
    Jhanwar, Yuliya
    Vallabhajosula, Shankar
    Christos, Paul J.
    Lam, Linda
    Epstein, Jennifer
    Karpenko, Irene
    Beltran, Himisha
    Nanus, David M.
    Goldsmith, Stanley J.
    Bander, Neil H.
    Tagawa, Scott T.
    CANCER RESEARCH, 2016, 76
  • [23] Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Whang, Young E.
    Kaur, Gurveen
    Vallabhajosula, Shankar
    Christos, Paul J.
    Nikolopoulou, Anastasia
    Jhanwar, Yuliya
    Sheikh, Arif
    Ireland, Adam
    Garcias-Espana, Carmen
    Goldsmith, Stanley J.
    Beltran, Himisha
    Bander, Neil Harrison
    Nanus, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
    Ling, Sui Wai
    de Blois, Erik
    Hooijman, Eline
    van der Veldt, Astrid
    Brabander, Tessa
    PHARMACEUTICS, 2022, 14 (10)
  • [25] PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Sandhu, Shahneen
    Joshua, Anthony M.
    Emmett, Louise
    Spain, Lavinia Anne
    Horvath, Lisa
    Crumbaker, Megan
    Anton, Angelyn
    Wallace, Roslyn
    Pasam, Anupama
    Bressel, Mathias
    Cassidy, Erin
    Banks, Patricia
    Dhiantravan, Nattakorn
    Akhurst, Timothy J.
    Kumar, Aravind Ravi
    Alipour, Ramin
    Scalzo, Mark
    Williams, Scott
    Hicks, Rodney
    Hofman, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Final results of 2-dose fractionation of 177mLu-J591 for progressive metastatic castration-resistant prostate cancer mCRPC).
    Tagawa, Scott T.
    Batra, Jaspreet
    Vallabhajosula, Shankar
    Jhanwar, Yuliya
    Christos, Paul J.
    Emmerich, Lauren
    Karir, Beerinder S.
    Karpenko, Irene
    Lam, Linda
    Febles, Victor R. A.
    Molina, Ana M.
    Beltran, Himisha
    Goldsmith, Stanley J.
    Bander, Neil Harrison
    Nanus, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
    Tauber, R. L.
    Feuerecker, B.
    Knorr, K.
    Beheshti, A.
    Seidl, C.
    D'Alessandria, C.
    Bruchertseifer, F.
    Retz, M.
    Gschwend, J. E.
    Weber, W.
    Morgenstern, A.
    Eiber, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] Phase I trial of fractionated-dose 177lutetium radiolabeled anti-specific membrane antigen (PSMA) monocional antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC)
    Tagawa, S. T.
    Vallabhajosula, S.
    Oshorne, J.
    Goldsmith, S. J.
    Petrillo, K.
    Tyrell, L.
    Dhillon, G. S.
    Beltran, H.
    Bander, N. H.
    Nanus, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [30] LuCAB: A phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Kostos, Louise Kathleen
    Buteau, James Patrick
    Kong, Grace
    Yeung, Theresa
    Di Iulio, Juliana
    Fahey, Michael T.
    Fettke, Heidi
    Furic, Luc
    Hofman, Michael S.
    Azad, Arun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345